BRAF and melanoma: Ipilimumab and pembrolizumab have been shown to target cytotoxic T-lymphocyte antigen 47 and programmed cell death protein 1,8 respectively, whereas vemurafenib targets BRAF signaling pathway.9 These therapies have prolonged the overall survival (OS) in patients with advanced melanoma.